WGS Stock Analysis: GeneDx Holdings | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 2.114m USD | 12M Return: -34.5% | US81663L2007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 47.4M
Qual. Beats: 1
Rev. Trend: 99.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GeneDx Holdings Corp. (NASDAQ: WGS) is a U.S.-based genomics company that provides genetic testing services, with a primary focus on pediatric and rare disease diagnostics using whole exome and genome sequencing. The company also offers data and information services and is developing an AI-based platform for sequencing analysis, interpretation, and clinical reporting across rare disease, hereditary risk, and cancer testing. Founded in 2000, GeneDx is headquartered in Stamford, Connecticut, and trades as a small-cap stock following its 2020 IPO.
Operating within the Health Care sector (GICS sub-industry: Health Care Equipment), GeneDx sits in the clinical diagnostics segment of the genomics market, where insurers, hospitals, and physicians pay for sequencing tests that inform patient care. Its investment in an AI-driven interpretation platform reflects a broader industry trend of using machine learning to reduce the time and labor required to convert raw sequencing data into clinically actionable reports, a key cost driver in next-generation sequencing workflows.
- Exome and genome test volumes drive accelerating revenue growth
- Path to profitability improves as gross margins expand steadily
- CMS reimbursement and FDA LDT rules shape test pricing
| Net Income: -106.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA -15.92 > 1.0 |
| NWC/Revenue: 37.79% < 20% (prev 36.83%; Δ 0.96% < -1%) |
| CFO/TA -0.10 > 3% & CFO -48.7m > Net Income -106.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.7m) vs 12m ago -0.15% < -2% |
| Gross Margin: 68.20% > 18% (prev 67.18%; Δ 1.01% > 0.5%) |
| Asset Turnover: 96.14% > 50% (prev 78.11%; Δ 18.03% > 0%) |
| Interest Coverage Ratio: -20.31 > 6 (EBIT TTM -60.6m / Interest Expense TTM 2.98m) |
| A: 0.36 (Total Current Assets 246.4m - Total Current Liabilities 74.6m) / Total Assets 481.5m |
| B: -3.02 (Retained Earnings -1.45b / Total Assets 481.5m) |
| C: -0.13 (EBIT TTM -60.6m / Avg Total Assets 472.7m) |
| D: 1.03 (Book Value of Equity 244.2m / Total Liabilities 237.3m) |
| Altman-Z'' = -7.29 = D |
| DSRI: 1.39 (Receivables 83.6m/48.0m, Revenue 454.4m/362.3m) |
| GMI: 0.99 (GM 67.18% / 68.20%) |
| AQI: 0.73 (AQ_t 0.31 / AQ_t-1 0.42) |
| SGI: 1.25 (Revenue 454.4m / 362.3m) |
| TATA: -0.12 (NI -106.4m - CFO -48.7m) / TA 481.5m) |
| Beneish M = -2.71 (Cap -4..+1) = A |
As of August 06, 2026, the stock is trading at USD 69.91 with a total of 867,061 shares traded. Over the past week, the price has changed by +9.77%, over one month by +1.48%, over three months by +102.58% and over the past year by -34.45%.
Current recommended Stop Loss: 63.50 (which is 9.2% or 1.2 ATR below the current price).
GeneDx Holdings has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy WGS.
- StrongBuy: 5
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 81.8 | 17% |
P/E Forward = 204.0816
P/S = 4.7549
P/B = 7.6076
Revenue TTM = 454.4m USD
EBIT TTM = -60.6m USD
EBITDA TTM = -35.4m USD
Long Term Debt = 48.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 5.71m USD (from shortTermDebt, last quarter)
Debt = 70.6m USD (from shortLongTermDebtTotal, last quarter) (leases 71.5m already included)
Net Debt = -62.0m USD (calculated: Debt 70.6m - CCE 132.5m)
Enterprise Value = 2.05b USD (2.11b + Debt 70.6m - CCE 132.5m)
Interest Coverage Ratio = -20.31 (Ebit TTM -60.6m / Interest Expense TTM 2.98m)
EV/FCF = -27.08x (Enterprise Value 2.05b / FCF TTM -75.8m)
FCF Yield = -3.69% (FCF TTM -75.8m / Enterprise Value 2.05b)
FCF Margin = -16.68% (FCF TTM -75.8m / Revenue TTM 454.4m)
Net Margin = -23.40% (Net Income TTM -106.4m / Revenue TTM 454.4m)
Gross Margin = 68.20% ((Revenue TTM 454.4m - Cost of Revenue TTM 144.5m) / Revenue TTM)
Gross Margin QoQ = 68.37% (prev 66.71%)
Tobins Q-Ratio = 4.26 (Enterprise Value 2.05b / Total Assets 481.5m)
Interest Expense / Debt = 4.23% (Interest Expense 2.98m / Debt 70.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -47.9m (EBIT -60.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.30 (Total Current Assets 246.4m / Total Current Liabilities 74.6m)
Debt / Equity = 0.29 (Debt 70.6m / totalStockholderEquity, last quarter 244.2m)
Debt / EBITDA = 1.75 (negative EBITDA) (Net Debt -62.0m / EBITDA -35.4m)
Debt / FCF = 0.82 (negative FCF - burning cash) (Net Debt -62.0m / FCF TTM -75.8m)
Total Stockholder Equity = 274.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -22.50% (Net Income -106.4m / Total Assets 481.5m)
RoE = -38.72% (Net Income TTM -106.4m / Total Stockholder Equity 274.7m)
RoCE = -18.77% (EBIT -60.6m / Capital Employed (Equity 274.7m + L.T.Debt 48.2m))
RoIC = -12.28% (negative operating profit) (NOPAT -47.9m / Invested Capital 389.8m)
WACC = 9.52% (E(2.11b)/V(2.18b) * Re(9.73%) + D(70.6m)/V(2.18b) * Rd(4.23%) * (1-Tc(0.21)))
Discount Rate = 9.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.94 | Cagr: 6.00%
[DCF] Fair Price = unknown (Cash Flow -75.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.86 | # QB: 1
Revenue Correlation: 98.98 | Revenue CAGR: 39.50% | SUE: 0.38 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.10 | Chg30d=-10.87% | Revisions=-62% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.06 | Chg30d=-158.00% | Revisions=-40% | GrowthEPS=-104.6% | GrowthRev=+11.9%
EPS next Year (2027-12-31): EPS=1.10 | Chg30d=-10.35% | Revisions=-25% | GrowthEPS=+1831.4% | GrowthRev=+24.4%
[Analyst] Revisions Ratio: -73% (up=0, down=8)